Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: Rapeuticsmd - The Real Truth

12 Health Care Stocks Moving In Tuesday's Intraday Session

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

TherapeuticsMD's Return On Capital Employed Overview

TherapeuticsMD's Return On Capital Employed Overview

TherapeuticsMD (NASDAQ:TXMD) brought in sales totaling $19.33 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 14.11%, resulting in a loss of $49.02 million.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Why TherapeuticsMD Stock Is Soaring Today

TherapeuticsMD Inc (NASDAQ: TXMD) shares are surging Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why TherapeuticsMD Shares Are Trading Higher Today

Why TherapeuticsMD Shares Are Trading Higher Today

TherapeuticsMD Inc (NASDAQ:TXMD) shares are trading higher after FDA approved the supplemental application, including minor revisions to Annovera's in vitro release testing specification that allowed for normal manufacturing variability. The FDA approved Annovera in August 2018 as the only long-lasting, reversible, procedure-free birth control. With the approval of the supplemental application, the company believes…

TherapeuticsMD: Q1 Earnings Insights

TherapeuticsMD: Q1 Earnings Insights

TherapeuticsMD (NASDAQ:TXMD) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings TherapeuticsMD missed estimated earnings by 18.0%, reporting an EPS of $-4.72 versus an estimate of $-4.0.

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

TherapeuticsMD: Q4 Earnings Insights

TherapeuticsMD: Q4 Earnings Insights

TherapeuticsMD (NASDAQ:TXMD) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

TherapeuticsMD Earnings Preview

TherapeuticsMD Earnings Preview

TherapeuticsMD (NASDAQ:TXMD) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that TherapeuticsMD will report an earnings per share (EPS) of $-0.08.

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Shares Soars After VitaCare Divestiture In $150M Deal

TherapeuticsMD Inc (NASDAQ:TXMD) has agreed to divest its VitaCare Prescription Services business to GoodRx Holdings Inc (NASDAQ:GDRX) for $150 million. VitaCare is a consumer-focused digital healthcare platform. TherapeuticsMD will also receive an additional $7 million in cash consideration contingent upon vitaCare's financial performance through 2023. TXMD will also enter into a long-term services agreement to…

Why TherapeuticsMD Shares Are Soaring Today

Why TherapeuticsMD Shares Are Soaring Today

TherapeuticsMD Inc (NASDAQ: TXMD) is trading higher Monday after the company announced it would sell its prescription services business, vitaCare, to GoodRx Holdings Inc (NASDAQ: GDRX).

Get all your
news in one place.

100's of premium titles.
One news app.

1

Organisations

Occidental Petroleum

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play